ID   Evsa-T GDC-0941-resistant clone 1
AC   CVCL_A1FL
DR   Cosmic; 2787555
DR   Wikidata; Q102113801
RX   PubMed=26759240;
CC   Selected for resistance to: ChEBI; CHEBI:65326; Pictrelisib (Pictilisib; GDC-0941).
CC   Sequence variation: Mutation; HGNC; 8976; PIK3CB; Simple; p.Asp1067Tyr (c.3199G>T); Zygosity=Heterozygous; Note=Responsible for pictrelisib resistance (PubMed=26759240).
CC   Sequence variation: Mutation; HGNC; 1748; CDH1; Simple; c.687+1_687+2delGT; ClinVar=VCV000483268; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Thr319fs*1 (c.951_954delACTT) (p.VL317fs) (V317fs*3); Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser241Cys (c.722C>G); ClinVar=VCV000177791; Zygosity=Homozygous (from parent cell line).
CC   Omics: Deep exome analysis.
CC   Derived from metastatic site: Ascites.
DI   NCIt; C4872; Breast carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens
HI   CVCL_1207 ! Evsa-T
SX   Female
AG   58Y
CA   Cancer cell line
DT   Created: 29-10-20; Last updated: 20-05-21; Version: 3
//
RX   PubMed=26759240; DOI=10.1158/0008-5472.CAN-15-2201;
RA   Nakanishi Y., Walter K., Spoerke J.M., O'Brien C., Huw L.Y.,
RA   Hampton G.M., Lackner M.R.;
RT   "Activating mutations in PIK3CB confer resistance to PI3K inhibition
RT   and define a novel oncogenic role for p110beta.";
RL   Cancer Res. 76:1193-1203(2016).
//